Fortress Biotech, Inc.: Form 10-K/A for the period ended Dec 31, 2020
Filed with the SEC on Apr 9, 2021 and accepted by EDGAR at Apr 9, 2021, 17:29 ET.
Sections
No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2020-01-01 to 2020-12-31 | $45.6m | us-gaap:Revenues |
| Cost of revenue | 12 months2020-01-01 to 2020-12-31 | $14.6m | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 12 months2020-01-01 to 2020-12-31 | $64.1m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2020-01-01 to 2020-12-31 | $61.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2020-01-01 to 2020-12-31 | −$94.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months2020-01-01 to 2020-12-31 | $136.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2020-01-01 to 2020-12-31 | −$46.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2020-01-01 to 2020-12-31 | −$0.65 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months2020-01-01 to 2020-12-31 | −$83.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2020-01-01 to 2020-12-31 | $1.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2020-01-01 to 2020-12-31 | $237.0k | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 12 months2020-01-01 to 2020-12-31 | $70.0k | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2020-12-31 | $233.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-12-31 | $261.6m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-12-31 | $328.8m | us-gaap:Assets |
| Current liabilities | At period end2020-12-31 | $48.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-12-31 | $131.8m | us-gaap:Liabilities |
| Long-term debt | At period end2020-12-31 | $51.7m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2020-12-31 | $100.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-21-004130. Last ingested by Listed: Nov 14, 2026, 11:27 ET. Listed shows no prices and gives no investment advice.